Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

221 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-13

Study Completion Date

2020-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

mPDia is a software that has been pre-learned based on a neurodegenerative parkinsonism diagnosis model using Nigrosome 1 MRI images, and clinical decision support system for diagnosing neurodegenerative parkinsonism by automatically analyzing Nigrosome 1 MRI images by assisting the medical team.

The specific aims of this study are to evaluate efficacy of mPDia for neurodegenerative Parkinsonism compared to the sensitivity and specificity levels of 18F FP-CIT PET/CT which is currently used to diagnose neurodegenerative parkinsonism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes

NCT00368199

Parkinson's Disease Parkinsonian Syndrome Multiple System Atrophy +4 more

COMPLETED

Subthalamic Nucleus Connectivity in Parkinson's Disease With Ultra-high Field Magnetic Resonance Imaging

NCT01981577

Parkinson Disease

UNKNOWN

PharmacoMRI of Parkinson Disease

NCT01528592

Parkinson's Disease

COMPLETED NA

Validation of DaTscan for Detection of Parkinson Disease Related Disorders

NCT02138682

Parkinson Disease Movement Disorders

UNKNOWN

18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging

NCT01283347

Parkinson's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diagnoses Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abnormal

The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism

mPDia

Intervention Type DEVICE

Clinical decision support system for diagnosing neurodegenerative parkinsonism

Normal

The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism

mPDia

Intervention Type DEVICE

Clinical decision support system for diagnosing neurodegenerative parkinsonism

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mPDia

Clinical decision support system for diagnosing neurodegenerative parkinsonism

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over 19 years old
* 3T nigrosome 1 MRI acquired
* 18F FP-CIT PET/CT are confirmed to be normal
* The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism

* Adults over 19 years old
* 3T nigrosome 1 MRI acquired
* 18F FP-CIT PET/CT are confirmed to be abnormal
* The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism

Exclusion Criteria

* Patients with other brain diseases except parkinsonism
* Who have anatomical abnormality in MRIs etc.
* Who have other causes of tremor(e.g., thyroid disease)
* Patients with lesion in basal ganglia(e.g., vascular parkinsonism, hydrocephalus and Wilson's disease)

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes